Scailyte, a company based at the site Novartis Campus of the Switzerland Innovation Park Basel Area, uses artificial intelligence (AI) to discover biomarkers. Scailyte has now announced a research collaboration with Visterra. Working with the biopharmaceutical company from Waltham, Massachusetts, in the USA, Scailyte aims to uncover disease patterns and new biomarkers for autoimmune diseases. The shared goal is developing treatments through biomarker discovery.

According to a press release, this collaboration will leverage Scailyte’s proprietary AI platform, ScaiVision. Founded in 2017 as a spin-off from the Swiss Federal Institute of Technology in Zurich, Scailyte uses the platform to analyze over 60 million single-cell profiles. The company’s extensive network of clinical partners and access to unique patient cohorts in oncology and auto-immunity have led to the development of multiple patent-pending biomarker signatures.

Accelerating much-needed therapies

Visterra, a clinical-stage biotech, specializes in biologics research and early-stage clinical development. It is committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. “By combining our AI-powered biomarker discovery platform with Visterra’s deep understanding of disease biology, we believe we can accelerate the development of much-needed therapies,” said Peter Nestorov, CEO at Scailyte.